- cafead   Jul 23, 2024 at 11:42: AM
via A clutch of Johnson & Johnson veterans have burst onto the biotech scene, launching Third Arc Bio with $165 million to take multifunctional antibodies into the clinic in solid tumors and autoimmune diseases.
article source
article source